Deuterium

Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment

Retrieved on: 
Thursday, January 20, 2022 - 12:28pm

The ongoing open-label Phase I study in Australia will evaluate the safety, pharmacokinetics, and anti-tumor activity of HP518 in patients with mCRPC.

Key Points: 
  • The ongoing open-label Phase I study in Australia will evaluate the safety, pharmacokinetics, and anti-tumor activity of HP518 in patients with mCRPC.
  • It has the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations.
  • HP518, discovered and developed by Hinova, is an orally bioavailable chimeric degrader targeting AR, with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations.
  • Hinova has committed to the discovery and development of innovative medicines for patients globally through deuteration and targeted protein degradation technologies.

Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC

Retrieved on: 
Thursday, January 13, 2022 - 12:00pm

Transformative acquisition significantly expands Salarius oncology pipeline into the targeted degradation space with ability to go after undruggable cancer-promoting targets, a rapidly growing area of cancer drug development with multi-billion-dollar market potential.

Key Points: 
  • Transformative acquisition significantly expands Salarius oncology pipeline into the targeted degradation space with ability to go after undruggable cancer-promoting targets, a rapidly growing area of cancer drug development with multi-billion-dollar market potential.
  • Acquisition includes a lead candidate, SP-3164 (formerly DRX-164), additional protein degrader programs, and the related intellectual property portfolio that includes issued composition of matter patents.
  • Targeted protein degradation takes advantage of the bodys own degradation system to promote the selective elimination of disease-causing proteins.
  • With SP-3164, Salarius plans to enter the protein degradation space which generated global sales of over $15 billion in 2020.

Hydrogen Optimized Signs Letter of Intent with Industrial Company to Supply More Than 40 MW of Large-Scale Hydrogen Production Capacity

Retrieved on: 
Monday, January 10, 2022 - 10:00am

"The signing of this LOI is a significant step forward in our commercialization process," said Andrew T. B. Stuart, President and CEO of Hydrogen Optimized.

Key Points: 
  • "The signing of this LOI is a significant step forward in our commercialization process," said Andrew T. B. Stuart, President and CEO of Hydrogen Optimized.
  • *
    Hydrogen Optimized is a private hydrogen technology company that develops and commercializes large-scale Green Hydrogen production systems.
  • As a sustainable energy conversion company, Hydrogen Optimized enables the conversion of green electricity into Green Hydrogen and the transformation of heavy fossil fuel-use industries into sustainability leaders.
  • Hydrogen Optimized seeks to be the first water electrolysis company to supply an aggregate of 10 GW of hydrogen production equipment.

Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Retrieved on: 
Tuesday, January 4, 2022 - 12:00pm

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment in THRIVE-AA2, the second Phase 3 clinical trial to evaluate the efficacy and safety of CTP543, an oral Janus kinase (JAK) inhibitor, in adult patients with moderate to severe alopecia areata.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment in THRIVE-AA2, the second Phase 3 clinical trial to evaluate the efficacy and safety of CTP543, an oral Janus kinase (JAK) inhibitor, in adult patients with moderate to severe alopecia areata.
  • Enrollment in the THRIVE-AA1 trial was completed in October 2021, and topline data is expected in the second quarter of 2022.
  • THRIVE-AA2 (NCT04797650) is a randomized, double-blind, placebo-controlled clinical trial in adult patients with moderate to severe alopecia areata at sites in the U.S., Canada and Europe evaluating the regrowth of scalp hair after 24 weeks of dosing using the Severity of Alopecia Tool (SALT).
  • Concerts lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition.

Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference

Retrieved on: 
Monday, January 3, 2022 - 12:00pm

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022.
  • The webcast of the presentation may be accessed in the Investors section of the Companys website at www.concertpharma.com .
  • A replay of the conference webcast will be available on Concerts website for two weeks following the presentation.
  • Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform (deuterated chemical entity platform).

LG Display Unveils Next-Generation OLED TV Display 'OLED EX'

Retrieved on: 
Wednesday, December 29, 2021 - 5:00am

SEOUL, South Korea, Dec.29,2021 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, unveiled today its newest OLED TV technology 'OLED EX'.

Key Points: 
  • SEOUL, South Korea, Dec.29,2021 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, unveiled today its newest OLED TV technology 'OLED EX'.
  • Since 2013, the year it became the first to mass produce OLED TV displays, LG Display has been consistently improving its leading OLED technology.
  • LG Display plans to strengthen its leadership and product competitiveness in the large-sized OLED business by integrating OLED EX technology into all OLED TV displays manufactured at its OLED production plants in Paju, South Korea, and in Guangzhou, China, starting from the second quarter of 2022.
  • LG Display Co., Ltd. [NYSE: LPL, KRX: 034220] is the world's leading innovator of display technologies, including thin-film transistor liquid crystal and OLED displays.

MHI Awarded Contract for Six Units of the Outer Vertical Target for the Divertor Used in the ITER in Southern France

Retrieved on: 
Tuesday, December 14, 2021 - 12:47am

The Outer Vertical Target is one of the parts in the divertor.

Key Points: 
  • The Outer Vertical Target is one of the parts in the divertor.
  • The divertor is one of the core components of the fusion reactor used in the tokamak.
  • The divertor comprises four parts: the Outer Vertical Target being procured by Japan, the Cassette Body and Inner Vertical Target being manufactured in the EU, and the Dome being made in Russia.
  • MHI previously awarded a contract from QST for manufacture of five (of a total of 19) toroidal field (TF) coils, another core component of ITER.

Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences

Retrieved on: 
Thursday, November 11, 2021 - 12:00pm

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a virtual fireside chat at The Jefferies London Healthcare Conference.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a virtual fireside chat at The Jefferies London Healthcare Conference.
  • The on-demand fireside chat will be available beginning at 8:00 a.m. GMT on November 18, 2021.
  • A webcast of the Jefferies fireside chat may be accessed in the Investors section of the Companys website at www.concertpharma.com .
  • Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform (deuterated chemical entity platform).

Lennham Pharmaceuticals Announces Discovery of Next Generation Testosterone Candidate

Retrieved on: 
Wednesday, November 10, 2021 - 2:06pm

Lennham Pharmaceuticals, a privately-held company focused on the creative use of deuterium chemistry to improve the metabolic and pharmacological profile of existing compounds, today announced the discovery and patenting of its next generation testosterone candidate, d3-testosterone.

Key Points: 
  • Lennham Pharmaceuticals, a privately-held company focused on the creative use of deuterium chemistry to improve the metabolic and pharmacological profile of existing compounds, today announced the discovery and patenting of its next generation testosterone candidate, d3-testosterone.
  • In non-clinical studies, d3-testosterone strongly resisted metabolism to the estrogen estradiol when compared to testosterone.
  • Lennhams non-clinical studies also demonstrated that d3-testosterone has similar androgen receptor agonist activity as testosterone.
  • Products containing testosterone and prodrugs of testosterone, such as testosterone undecanoate, have been approved for use by FDA to treat certain conditions such as male hypogonadism and delayed puberty.

Concert Pharmaceuticals Announces $65 Million Financing

Retrieved on: 
Thursday, November 4, 2021 - 11:00am

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into an agreement with BVF Partners L.P. (BVF) and RA Capital Management (RA) to raise gross proceeds of $65 million.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into an agreement with BVF Partners L.P. (BVF) and RA Capital Management (RA) to raise gross proceeds of $65 million.
  • In addition, Concert will have the potential to receive an additional $103 million upon the full exercise of warrants being issued in connection with the agreement.
  • With the $65 million raised in this financing, Concert now expects to be able to fund its operations into the fourth quarter of 2022.
  • Pursuant to this financing, BVF and RA will also receive a portion of potential future AVP-786 royalties currently payable to Concert by Avanir.